David Mohler

David Mohler has an extensive background in helping pharmaceutical, healthcare and life sciences companies develop effective strategies to deal with federal regulatory issues. He advises clients on Medicare coverage and reimbursement issues, and uses his knowledge of legislative and administrative processes to advise on pricing regulation, FDA compliance, and general public policy advocacy. Before joining Foley Hoag, David spent eight years with the Pharmaceutical Research and Manufacturers of America (PhRMA) in Washington, DC, an organization representing research-based pharmaceutical and biotechnology companies. His responsibilities there progressed from Director of Federal Affairs to Vice President of Congressional Relations and Senior Vice President of Federal Affairs. As Senior Vice President David served as chief policy and political advocate for PhRMA members before House and Senate Committees as well as with the White House and other administrative agencies such as the Department of Health and Human Services, and the Department of Commerce. At PhRMA, David helped the industry successfully navigate a period of intense legislative and regulatory activity. Legislative matters in which he was involved included reauthorization of the Prescription Drug User Fee Act and the Better Pharmaceuticals for Children Act, enactment of the Medicare Modernization Act of 2003, major reforms to the Hatch Waxman Amendments, the 2005 budget reconciliation process and enactment of the Deficit Reduction Act, and the creation of the new Medicare Part D prescription drug benefit. His work in this area built on his earlier PhRMA responsibilities, in which he served as a policy advocate in Congress for issues involving intellectual property, pricing regulation and government procurement. David had earlier served as Manager of Federal Affairs for a major pharmaceutical company, where he was responsible for a wide range of legislative issues dealing with intellectual property, tort reform, FDA compliance, animal health, Medicaid reimbursement and health care reform. As part of his work he was chair of the Animal Health Institute's Government Affairs Committee. David has also been associated with a Washington, DC law firm, where his health legal practice focused on intellectual property, FDA regulation, and Medicare reimbursement.